314 related articles for article (PubMed ID: 23382571)
21. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania.
Mapesi H; Okuma J; Franzeck F; Wilson HI; Senkoro E; Byakuzana T; Ndege R; Vanobberghen F; Glass TR; Battegay M; Weisser M; Paris DH;
PLoS One; 2021; 16(12):e0261367. PubMed ID: 34910776
[TBL] [Abstract][Full Text] [Related]
23. Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate.
Dietrich LG; Barceló C; Thorball CW; Ryom L; Burkhalter F; Hasse B; Furrer H; Weisser M; Steffen A; Bernasconi E; Cavassini M; de Seigneux S; Csajka C; Fellay J; Ledergerber B; Tarr PE
Clin Infect Dis; 2020 Feb; 70(5):890-897. PubMed ID: 30953057
[TBL] [Abstract][Full Text] [Related]
24. Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy.
Zhao Y; Zhang M; Shi CX; Zhang Y; Cai W; Zhao Q; Li Y; Li H; Liu X; Chen L; Ma Y; Zhang F; Liu Z; Wu Z
PLoS One; 2015; 10(8):e0135462. PubMed ID: 26317657
[TBL] [Abstract][Full Text] [Related]
25. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM
AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630
[TBL] [Abstract][Full Text] [Related]
27. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
[TBL] [Abstract][Full Text] [Related]
28. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
Lee JE; Lee S; Song SH; Kwak IS; Lee SH
Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
[TBL] [Abstract][Full Text] [Related]
29. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.
Drak D; Barratt H; Templeton DJ; O'Connor CC; Gracey DM
PLoS One; 2019; 14(1):e0210106. PubMed ID: 30653509
[TBL] [Abstract][Full Text] [Related]
30. A clinically useful risk-score for chronic kidney disease in HIV infection.
Mocroft A; Lundgren J; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Heuhaus J; Fux C; Moranne O; Morlat P; Johnson M; Ryom L;
J Int AIDS Soc; 2014; 17(4 Suppl 3):19514. PubMed ID: 25394023
[TBL] [Abstract][Full Text] [Related]
31. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
32. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
33. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
[TBL] [Abstract][Full Text] [Related]
34. Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?
Flandre P; Pugliese P; Allavena C; Isnard Bagnis C; Cuzin L;
AIDS; 2016 Jun; 30(9):1433-8. PubMed ID: 26891036
[TBL] [Abstract][Full Text] [Related]
35. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
36. Effects of aging, baseline renal function and stage of HIV infection on post-treatment changes in renal function among HIV-infected patients: a retrospective cohort study.
Ding Y; Duan S; Ye R; Yao S; Cao D; Yang Y; Wang J; Shi Y; Zhang Y; Li P; Xu Y; Wei H; Yin C; Liu X; He N
HIV Med; 2019 Oct; 20(9):591-600. PubMed ID: 31274235
[TBL] [Abstract][Full Text] [Related]
37. Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.
Kooij KW; Vogt L; Wit FWNM; van der Valk M; van Zoest RA; Goorhuis A; Prins M; Post FA; Reiss P;
J Infect Dis; 2017 Sep; 216(6):622-631. PubMed ID: 28934420
[TBL] [Abstract][Full Text] [Related]
38. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
[TBL] [Abstract][Full Text] [Related]
39. Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.
Ryom L; Lundgren JD; Ross M; Kirk O; Law M; Morlat P; Fontas E; Smit C; Fux CA; Hatleberg CI; de Wit S; Sabin CA; Mocroft A;
J Infect Dis; 2016 Oct; 214(8):1212-20. PubMed ID: 27485357
[TBL] [Abstract][Full Text] [Related]
40. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
